Literature DB >> 3016109

The role of parvovirus B19 in aplastic crisis and erythema infectiosum (fifth disease).

T Chorba, P Coccia, R C Holman, P Tattersall, L J Anderson, J Sudman, N S Young, E Kurczynski, U M Saarinen, R Moir.   

Abstract

In 1984, simultaneous outbreaks of aplastic crisis and erythema infectiosum occurred in northeastern Ohio. Sera were analyzed from 26 patients with aplastic crisis: 24 had IgM specific for parvovirus B19, five had B19-like particles by electron microscopy, and 13 had DNA from B19; no sera from 33 controls had evidence of recent infection with B19 (P less than .0001). DNA from B19 was also detected in specimens of throat gargle and urine from two patients with aplastic crisis. Sera from 36 of 51 children with erythema infectiosum had B19-specific IgM, compared with serum from one of 42 susceptible controls (P less than .0001). DNA from B19 was detected in sera from only two of 51 patients who had erythema infectiosum. The secondary attack rates among susceptible contacts decreased with age (overall total, 49.6%). Differential rates of asymptomatic infection were observed among black (68.8%) and white (20.0%) household members (P = .003). These were the first identified simultaneous outbreaks of aplastic crisis and erythema infectiosum. Their occurrence provided an opportunity to study the epidemiology and spectrum of B19 infection with geographically and temporally matched comparison groups; our results support the hypothesis that infection with parvovirus causes these two clinical entities.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3016109     DOI: 10.1093/infdis/154.3.383

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  34 in total

Review 1.  Parvovirus B19 infection in human pregnancy.

Authors:  R F Lamont; J D Sobel; E Vaisbuch; J P Kusanovic; S Mazaki-Tovi; S K Kim; N Uldbjerg; R Romero
Journal:  BJOG       Date:  2010-10-13       Impact factor: 6.531

2.  Suppression of virus-specific antibody production by CD8+ class I-restricted antiviral cytotoxic T cells in vivo.

Authors:  D Moskophidis; H Pircher; I Ciernik; B Odermatt; H Hengartner; R M Zinkernagel
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

3.  Functional mapping of the genome of the B19 (human) parvovirus by in vitro translation after negative hybrid selection.

Authors:  K Ozawa; J Ayub; N Young
Journal:  J Virol       Date:  1988-07       Impact factor: 5.103

4.  T helper cell-mediated interferon-gamma expression after human parvovirus B19 infection: persisting VP2-specific and transient VP1u-specific activity.

Authors:  R Franssila; J Auramo; S Modrow; M Möbs; C Oker-Blom; P Käpylä; M Söderlund-Venermo; K Hedman
Journal:  Clin Exp Immunol       Date:  2005-10       Impact factor: 4.330

5.  Expression of an antigenic polypeptide of the human parvovirus B19.

Authors:  H Eiffert; H G Köchel; M Heuer; J D Tratschin; R Thomssen
Journal:  Med Microbiol Immunol       Date:  1990       Impact factor: 3.402

Review 6.  Erythema infectiosum and pregnancy-related complications.

Authors:  M Levy; S E Read
Journal:  CMAJ       Date:  1990-11-01       Impact factor: 8.262

7.  Immune response to B19 parvovirus and an antibody defect in persistent viral infection.

Authors:  G J Kurtzman; B J Cohen; A M Field; R Oseas; R M Blaese; N S Young
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

Review 8.  Human parvovirus B19.

Authors:  Erik D Heegaard; Kevin E Brown
Journal:  Clin Microbiol Rev       Date:  2002-07       Impact factor: 26.132

9.  Parvovirus B19 outbreak on an adult ward.

Authors:  C Seng; P Watkins; D Morse; S P Barrett; M Zambon; N Andrews; M Atkins; S Hall; Y K Lau; B J Cohen
Journal:  Epidemiol Infect       Date:  1994-10       Impact factor: 2.451

10.  Acute obstructive respiratory diseases in infants and children associated with parvovirus B19 infection.

Authors:  S Wiersbitzky; T F Schwarz; R Bruns; E H Ballke; M Roggendorf; H Wiersbitzky; F Deinhardt
Journal:  Infection       Date:  1991 Jul-Aug       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.